Synpromics collaborates with UCL to generate a range of synthetic gene promoters for the CNS to develop a gene therapy for Parkinson’s disease.
Synpromics Ltd, the leader in gene control, is listed by The Scotsman as one of the top 5 leading innovative companies in life sciences in Scotland.
In a recent blog by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, Synpromics is listed as one of 7 prominent players in the UK’s thriving synthetic biology sector .
Synpromics have been awarded Best Emerging UK Synthetic Biotech Company at the 2017 OBN Awards for enabling safer, more effective cell and gene medicines.
David Venables, CEO of Synpromics, will sit on the panel ‘Gene Therapy: Building the gene medicine pipeline through next generation technologies’ on the 4th October at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California.